In a recent decision, the Centers for Medicare and Medicaid Services have declined a proposal to expand Medicare coverage for ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...